A. baumannii is a non-motile, oxidase-negative, aerobic, and non-fermenting Gram-negative coccobacillus that is mostly seen among hospitalized patients, especially in the intensive care units (ICU) (
1). This organism creates a wide range of infections such as ventilator-associated pneumonia (VAP), pneumonia, endocarditis, skin infections, bacteremia, wound infection, urinary tract infection, and meningitis (
2). In different species of
Acinetobacter, the acquisition and dissemination of a drug-resistant determinant in community and hospitals are greatly facilitated by horizontal gene transfer of genetic mobile elements such as transposons, plasmids, and integrons. Among these genetic mobile elements, integrons are important because of their capacity for expressing and carrying resistance genes (
3). Recently, due to the high use of antibiotics, extensive antibiotic resistant and multidrug-resistant
A. baumannii (XDR-AB, and MDR-AB) have emerged as a major problem worldwide (
1).
The use of broad-spectrum antibiotics, as well as the transmission of strains among patients, created a selective pressure that led to the emerging of MDR-AB (
4). The most important challenge for clinical microbiologists and physicians is the management of MDR
Acinetobacter spp. infections. Ability to survive in clinical settings makes it a common agent for healthcare-associated infections which leads to multiple outbreaks. Spectrums of infections due to MDR
Acinetobacter spp. contain pneumonia, UTI, bacteremia, wound infection, and meningitis.
A. baumannii is intrinsically resistant to antibiotic agents, which is due to the expression of active efflux pump systems; the low expression of outer membrane porins; having a resistance island, which contains a cluster of genes encoding antibiotic; and heavy metal resistance, which causes resistance to ammonium-based disinfectants (
5).
A. baumannii shows several mechanisms to resist multiple antibiotic classes, including the production of antibiotic degradation/modification enzymes, decreased permeability, active drug efflux pumps, modification in drug targets, and biofilm formation (
6). It is also difficult to control
A. baumannii because it can survive in hospital settings for a long time. The potential of
A. baumannii to demonstrate multiple antibiotic resistance and biofilm formation may be involved in the ability to survive in the environment (
7). Biofilm formation on all surfaces is a good strategy for increasing the chances of bacterial survival in stressful conditions following environmental conditions or antibiotic treatment (
6,
7). Increasing the synthesis of exopolysaccharides and also the development of drug resistance are sometimes associated with biofilm production (
8). Many factors are involved in the formation of biofilms, including outer membrane protein A (OmpA), biofilm-associated protein (
Bap), beta-lactamase
PER-1, iron uptake mechanism, and the
CsuA/BABCDE chaperone-usher pili assembly system (
9). Some surface proteins such as
ompA,
blaPER-1, and
Bap, in addition to being involved in biofilm formation, are also involved in the bacterial attachment to human epithelial cells and abiotic surfaces (
10).
The expression of the
CsuA/BABCDE chaperon-usher complex is needed for the assembly and production of pili contributing to adhesion to abiotic surfaces (
11). It has been shown that inactivation of the
csuE gene inhibits the production of pili as well as biofilm formation (
12). The expression of
csu operon is controlled by a two-component regulatory system, including a response regulator encoded by bfmR and a sensor kinase encoded by bfmS. Translational and transcriptional analyses show that the inactivation of
bfmR prevents the expression of this operon and the consequent inactivation of both pili production and biofilm formation (
13). In addition, the
blaPER-1 gene is also associated with increased biofilm formation and increased bacterial attachment to the abiotic surfaces and human epithelial cells (
10).